Literature DB >> 8018538

Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing mice.

A Turner1, D J King, A P Farnsworth, S K Rhind, R B Pedley, J Boden, R Boden, T A Millican, K Millar, B Boyce.   

Abstract

A novel 111In ligand (a C-functionalised derivative of 1,4,7-triazacyclononanetriacetic acid), termed 9N3, was covalently attached to chimeric B72.3, labelled with 111In and compared with 111In-labelled chimeric B72.3 diethylenetriaminepentaacetic acid (DTPA) cyclic anhydride conjugate (cDTPA) and a C-linked derivative of DTPA (CT-DTPA) in athymic mice bearing human colon carcinoma xenografts. Significant differences in biodistribution were observed between 9N3 and cDTPA conjugates especially in the tumour uptake and blood, liver, femur and colon levels at 24, 48 and 144 h. Significantly higher tumour uptake was observed for 111In-cB72.3-9N3 compared with 111In-cB72.3-cDTPA at all time points. Radiolocalisation (RI) indices increased with time for the 9N3 conjugate but remained constant for the cDTPA conjugate. The biodistribution of 111In-labelled cB72.3-CT-DTPA was similar to that of 111In-labelled cB72.3-9N3 except for elevated kidney levels. A 12N4 macrocycle (a C-functionalised derivative of 1,4,7,10-tetraazacyclododecanetetraacetic acid) was also tested for its ability to chelate 111In and its biodistribution examined. Labelled conjugates with this macrocycle were more difficult to prepare in a stable form but gave a very similar biodistribution to the 9N3 macrocycle conjugate. Macrocycle-antibody conjugates of this type offer considerable promise for tumour imaging in patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018538      PMCID: PMC2033299          DOI: 10.1038/bjc.1994.246

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

Review 1.  Engineering antibodies for therapy.

Authors:  J R Adair
Journal:  Immunol Rev       Date:  1992-12       Impact factor: 12.988

2.  Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against alpha-fetoprotein.

Authors:  H Sakahara; K Endo; T Nakashima; M Koizumi; H Ohta; K Torizuka; T Furukawa; Y Ohmomo; A Yokoyama; K Okada
Journal:  J Nucl Med       Date:  1985-07       Impact factor: 10.057

3.  New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts.

Authors:  J M Esteban; J Schlom; O A Gansow; R W Atcher; M W Brechbiel; D E Simpson; D Colcher
Journal:  J Nucl Med       Date:  1987-05       Impact factor: 10.057

4.  Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients.

Authors:  D J Hnatowich; T W Griffin; C Kosciuczyk; M Rusckowski; R L Childs; J A Mattis; D Shealy; P W Doherty
Journal:  J Nucl Med       Date:  1985-08       Impact factor: 10.057

5.  Pharmacokinetics of the monoclonal antibody B72.3 and its fragments labeled with either 125I or 111In.

Authors:  B A Brown; R D Comeau; P L Jones; F A Liberatore; W P Neacy; H Sands; B M Gallagher
Journal:  Cancer Res       Date:  1987-02-15       Impact factor: 12.701

6.  Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.

Authors:  D Colcher; D Milenic; M Roselli; A Raubitschek; G Yarranton; D King; J Adair; N Whittle; M Bodmer; J Schlom
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

7.  Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions.

Authors:  C F Meares; M J McCall; D T Reardan; D A Goodwin; C I Diamanti; M McTigue
Journal:  Anal Biochem       Date:  1984-10       Impact factor: 3.365

8.  Relative reactivity of DTPA, immunoreactive antibody-DTPA conjugates, and nonimmunoreactive antibody-DTPA conjugates toward indium-111.

Authors:  C H Paik; J J Hong; M A Ebbert; S C Heald; R C Reba; W C Eckelman
Journal:  J Nucl Med       Date:  1985-05       Impact factor: 10.057

9.  The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method.

Authors:  D J Hnatowich; R L Childs; D Lanteigne; A Najafi
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

10.  Development of a metastatic human colon cancer xenograft model in the nude mouse.

Authors:  J Lundy; J W Greiner; D Colcher
Journal:  J Surg Oncol       Date:  1986-04       Impact factor: 3.454

View more
  4 in total

1.  Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Authors:  J L Casey; D J King; L C Chaplin; A M Haines; R B Pedley; A Mountain; G T Yarranton; R H Begent
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

2.  Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.

Authors:  D Marshall; R B Pedley; J A Boden; R Boden; R G Melton; R H Begent
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

3.  Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.

Authors:  D J King; P Antoniw; R J Owens; J R Adair; A M Haines; A P Farnsworth; H Finney; A D Lawson; A Lyons; T S Baker
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

4.  The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.

Authors:  R B Pedley; J A Boden; R Boden; R H Begent; A Turner; A M Haines; D J King
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.